About Skyepharma

Skyepharma was established in 1996, by the acquisition of Jago Pharma AG, which had been a drug delivery specialist since 1983. Today Skyepharma is a leading expert drug delivery company with a proven range of oral and inhalation product development capabilities and technologies.

Our research and development laboratories are located in Muttenz, near Basel in Switzerland, where our experienced teams of scientists formulate and develop innovative inhalation and oral modified release pharmaceutical products. Our proven capabilities in solving complex formulation issues, combined with pre-clinical, clinical and regulatory expertise and the application of proprietary technologies has resulted in 14 currently approved products that are sold in over 80 countries. The products are marketed throughout the world by both large pharmaceutical companies and specialty pharmaceutical companies.

Skyepharma enhances its product pipeline by adding innovative products arising from its own research as well as work done in collaboration with partners. The Group's formulation and development capabilities and enabling technologies in the areas of inhaled and oral controlled drug delivery are available to other pharmaceutical companies on a partnered development and licensing basis.

Skyepharma's headquarters are in London, and its shares are traded on the London Stock Exchange under the symbol SKP.

Skyepharma laboratories develop oral and inhalation pharmaceutical products

Copyright 2014, Skyepharma. All Rights Reserved. Skyepharma PLC is a public limited company registered in England and Wales, registration number 0107582.
Registered office: 46-48 Grosvenor Gardens, London SW1W 0EB, United Kingdom

Contact addresses

Skyepharma PLC
46-48 Grosvenor Gardens

Tel: +44 207 881 0524

Fax: +44 207 881 1199

E-mail us

Skyepharma AG
Eptingerstrasse 61
4132 Muttenz

Tel: +41 61 467 5555

Fax: +41 61 467 5500

E-mail us

This website works best using cookies.